N-succinimidyl 3-[211At]astato-4-guanidinomethylbenzoate: an acylation agent for labeling internalizing antibodies with α-particle emitting 211At

This publication has 20 references indexed in Scilit:

• Radioimmunotherapy for Acute Leukemia
  Cancer Control, 2002
• Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis
  International Journal of Cancer, 2002
• Therapeutic advantages of Auger electron- over β-emitting radiometals or radioiodine when conjugated to internalizing antibodies
  European Journal of Nuclear Medicine and Molecular Imaging, 2000
• Synthesis, purification, and in vitro stability of 211At- and 125I-labeled amidobisphosphonates
  Nuclear Medicine and Biology, 1999
• Labeling of Monoclonal Antibodies with Diethylenetriaminepentaacetic Acid-Appended Radioiodinated Peptides Containingd-Amino Acids
  Bioconjugate Chemistry, 1999
• Evaluation of an internal cyclotron target for the production of 211At via the 209Bi (α,2n)211At reaction
  Applied Radiation and Isotopes, 1996
• Receptor blockade with monoclomal antibodies as anti-cancer therapy
  Pharmacology & Therapeutics, 1994
• Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial
  International Journal of Radiation Oncology*Biology*Physics, 1992
• Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails.
  Proceedings of the National Academy of Sciences, 1992
• Determination of the immunoreactive function of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess
  Journal of Immunological Methods, 1984